Invesaro

Stocks Health care MEDS

NASDAQ · Health care

DataMeds AI, Inc. (MEDS)

DataMeds AI, Inc. brought in $8M of revenue over the twelve months to June 30, 2026. It posted a net loss of $88.3M. At June 30, 2026 it held $2.5M in cash against $31.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 17, 2026.

Watch MEDS in 60 seconds
Price
$3.11
-11.14% on the day · September 25, 2026
52-week range $0.82 to $73.00
Market cap
$9.1M
Revenue (last 12 months)
$8M
Net margin
-1,100.3%

What DataMeds AI, Inc. does

DataMeds AI, Inc. is registered with the SEC under industry code SIC 5122 (Wholesale-Drugs, Proprietaries & Druggists' Sundries). Its shares trade on NASDAQ under the ticker MEDS.

Revenue and profit by year

Revenue
FY24: $18.1M $18.1M FY24FY25: $23.3M $23.3M FY25
Net income
FY24: -$2.9M -$2.9M FY24FY24: -$6.9M -$6.9M FY24FY25: -$101.3M -$101.3M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$23.3M-$93.7M-$101.3M-$1.43n/a
2024$18.1M-$6.1M-$6.9M-$0.15n/a
2024n/a-$2.9M-$2.9M-$0.06n/a

Full financial statements: income, balance sheet and cash flow

Where MEDS ranks in Health care

Revenue$23.3M
#426 of 646 in Health care · Bottom 34%
Revenue growth+28.7%
#126 of 474 in Health care · Top 26%
Net margin-433.9%
#456 of 485 in Health care · Bottom 6%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What DataMeds AI, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 17, 2026
  2. September 16, 2026
  3. August 31, 2026
  4. August 18, 2026
  5. August 17, 2026
    Quarterly report 10-Q · period to June 30, 2026Revenue fell 77% to $1.8M versus the same quarter last year; diluted EPS -$7.13 versus -$5.40.
  6. August 14, 2026
  7. August 14, 2026
  8. August 7, 2026
  9. August 4, 2026
  10. July 29, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 25, 2026. Insider transactions on SEC

Insider trades

What the people running DataMeds AI, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
June 22, 2026 Patel PrashantChief Executive Officer, Director Exercised options 100,000 $0.01 $500 Form 4
June 22, 2026 Ajjarapu Surendra KDirector Exercised options 100,000 $0.01 $500 Form 4
March 31, 2026 Patel PrashantChief Executive Officer, Director Received as pay 5,000,000 $0.20 $1M Form 4
March 31, 2026 Ajjarapu Surendra KDirector Received as pay 5,000,000 $0.20 $1M Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns MEDS

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

We have not read this company's Schedule 13D and 13G filings yet.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

2 insiders reported holding 540,010 shares in total, about $1.7M at the last price.

HolderSharesAs of
Patel PrashantChief Executive Officer, Director 282,365 June 22, 2026
Ajjarapu Surendra KDirector 257,645 June 22, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about MEDS

What does DataMeds AI, Inc. do?

DataMeds AI, Inc. is registered with the SEC under industry code SIC 5122 (Wholesale-Drugs, Proprietaries & Druggists' Sundries). Its shares trade on NASDAQ under the ticker MEDS.

Is DataMeds AI, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $88.3M on revenue of $8M.

How much revenue does DataMeds AI, Inc. make?

Over the twelve months to June 30, 2026 DataMeds AI, Inc. reported revenue of $8M.

When did DataMeds AI, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 17, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 17, 2026.

Similar companies

Compare MEDS with

Compare MEDS with any company

Follow MEDS

Get an email when DataMeds AI, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow MEDS: get an email when it files

Where the numbers come from

Financial figures are the values DataMeds AI, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.